Last edition
News about "myotonic dystrophy type 1"
Novartis Updates Phase 3 HARBOR Study of Del-desiran for DM1
Novartis reports del-desiran showed clinical activity in secondary endpoints and exploratory analyses in the phase 3 HARBOR study for DM1.
Myotonic Dystrophy Type 1 | 09/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members